Importantly, HDAC inhibitors significantly enhance the response to PD1 blockade therapy in multiple lung tumor models, indicating that the combination of HDAC inhibitors and PD1 blockade therapy represents a promising strategy for lung cancer treatment. The gene discussed is HDAC9; the disease is lung cancer.